首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   321759篇
  免费   19570篇
  国内免费   476篇
耳鼻咽喉   4444篇
儿科学   11015篇
妇产科学   10789篇
基础医学   48088篇
口腔科学   7849篇
临床医学   26779篇
内科学   60916篇
皮肤病学   7034篇
神经病学   23300篇
特种医学   12627篇
外国民族医学   44篇
外科学   50639篇
综合类   8130篇
现状与发展   1篇
一般理论   191篇
预防医学   22130篇
眼科学   7793篇
药学   22629篇
中国医学   805篇
肿瘤学   16602篇
  2021年   2556篇
  2019年   2609篇
  2018年   4057篇
  2017年   3015篇
  2016年   3472篇
  2015年   3930篇
  2014年   5267篇
  2013年   8214篇
  2012年   10554篇
  2011年   11012篇
  2010年   7011篇
  2009年   6345篇
  2008年   10153篇
  2007年   11067篇
  2006年   10914篇
  2005年   10566篇
  2004年   10244篇
  2003年   9644篇
  2002年   9214篇
  2001年   13745篇
  2000年   13985篇
  1999年   11792篇
  1998年   3365篇
  1997年   3106篇
  1996年   2930篇
  1995年   2820篇
  1994年   2584篇
  1992年   8613篇
  1991年   8727篇
  1990年   8507篇
  1989年   8312篇
  1988年   7522篇
  1987年   7271篇
  1986年   6923篇
  1985年   6756篇
  1984年   4985篇
  1983年   4338篇
  1982年   2718篇
  1979年   4606篇
  1978年   3415篇
  1977年   2902篇
  1976年   2626篇
  1975年   2973篇
  1974年   3508篇
  1973年   3477篇
  1972年   3220篇
  1971年   3035篇
  1970年   2908篇
  1969年   2666篇
  1968年   2595篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
Two Janus-associated kinase inhibitors (JAKi) (initially ruxolitinib and, more recently, fedratinib) have been approved as treatment options for patients who have intermediate-risk and high-risk myelofibrosis (MF), with pivotal trials demonstrating improvements in spleen volume, disease symptoms, and quality of life. At the same time, however, clinical trial experiences with JAKi agents in MF have demonstrated a high frequency of discontinuations because of adverse events or progressive disease. In addition, overall survival benefits and clinical and molecular predictors of response have not been established in this population, for which the disease burden is high and treatment options are limited. Consistently poor outcomes have been documented after JAKi discontinuation, with survival durations after ruxolitinib ranging from 11 to 16 months across several studies. To address such a high unmet therapeutic need, various non-JAKi agents are being actively explored (in combination with ruxolitinib in first-line or salvage settings and/or as monotherapy in JAKi-pretreated patients) in phase 3 clinical trials, including pelabresib (a bromodomain and extraterminal domain inhibitor), navitoclax (a B-cell lymphoma 2/B-cell lymphoma 2-xL inhibitor), parsaclisib (a phosphoinositide 3-kinase inhibitor), navtemadlin (formerly KRT-232; a murine double-minute chromosome 2 inhibitor), and imetelstat (a telomerase inhibitor). The breadth of data expected from these trials will provide insight into the ability of non-JAKi treatments to modify the natural history of MF.  相似文献   
3.

Objectives

To determine: (i) the behaviour change techniques used by a sample of Australian physiotherapists to promote non-treatment physical activity; and (ii) whether those behaviour change techniques are different to the techniques used to encourage adherence to rehabilitation exercises.

Design

Cross-sectional survey.

Method

An online self-report survey was advertised to private practice and outpatient physiotherapists treating patients with musculoskeletal conditions. The use of 50 behaviour change techniques were measured using five-point Likert-type scale questions.

Results

Four-hundred and eighty-six physiotherapists responded to the survey, with 216 surveys fully completed. Most respondents (85.1%) promoted non-treatment physical activity often or all of the time. Respondents frequently used 29 behaviour change techniques to promote non-treatment physical activity or encourage adherence to rehabilitation exercises. A similar number of behaviour change techniques was frequently used to encourage adherence to rehabilitation exercises (n = 28) and promote non-treatment physical activity (n = 26). Half of the behaviour change techniques included in the survey were frequently used for both promoting non-treatment physical activity and encouraging adherence to rehabilitation exercises (n = 25). Graded tasks was the most, and punishment was the least, frequently reported technique used to promote non-treatment physical activity and encourage adherence to rehabilitation exercises.

Conclusions

Respondents reported using similar behaviour change techniques to promote non-treatment physical activity and encourage adherence to rehabilitation exercises. The variability in behaviour change technique use suggests the behaviour the physiotherapist is promoting influences their behaviour change technique choice. Including the frequently-used behaviour change techniques in non-treatment physical activity promotion interventions might improve their efficacy.  相似文献   
4.
5.
6.
7.
8.
9.
10.
Henna, derived from a combination of natural leaves and coloring additives, is a common decorative dye traditionally used in many Islamic religious celebrations. Para‐phenylenediamine (PPD), a major component of black henna tattoo, is a strong sensitizer and common allergen. We report a case of severe connubial allergic contact dermatitis after black henna heterotransfer in a girl.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号